RPTX News and Press, Repare Therapeutics Inc. From 05/09/23

2023-05-09 17:39:17 ET Repare Therapeutics press release ( NASDAQ: RPTX ): Q1 GAAP EPS of -$0.83 misses by $0.03 . Revenue of $5.67M (+1282.9% Y/Y) misses by $0.45M . For further details see: Repare Therapeutics GAAP EPS of -$0.83 misses by $0.03, revenue...

Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’s upcoming ann...

Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safety and tolerability profile Combination results showed most benefit in late-line ovarian cancer de...

2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...

2023-03-09 02:23:23 ET Summary Today, we take our first look at a promising developmental concern called Repare Therapeutics. The company has significant collaboration deals with drug giants Roche and Bristol-Myers Squibb as well as some early-stage candidates in its pipeline. ...

Repare Therapeutics press release ( NASDAQ: RPTX ): Q4 GAAP EPS of -$0.75 misses by $0.02 . Revenue of $18.2M (+164.5% Y/Y) beats by $9.87M . For further details see: Repare Therapeutics GAAP EPS of -$0.75 misses by $0.02, revenue of $18.2M beats by $9.87M

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022. “We made substantial progress advancing o...

Cathie Wood – the billionaire investor who recently called her flagship fund “the new Nasdaq” has been loading up on shares of the following two small-cap stocks in recent days. Velo3D Inc ( NYSE: VLD ) The first one that’s caught her eye is this Velo3D...

Cancer-focused biotech Repare Therapeutics ( NASDAQ: RPTX ) lost ~5% on Friday after Morgan Stanley downgraded it, citing concerns over an upcoming Phase 1 readout for the company’s PKMYT1 inhibitor RP-6306. The rating change comes as Repare ( RPTX ) runs Phase 1 studie...